Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency

2014 ◽  
Vol 50 (4) ◽  
pp. 746-752 ◽  
Author(s):  
Ki Hyang Kim ◽  
Ho Young Kim ◽  
Hye Ryun Kim ◽  
Jong-Mu Sun ◽  
Ho Yeong Lim ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Renal Insufficiency ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell

Efficacy and toxicity of targeted therapies in patients with metastatic renal cell carcinoma with renal insufficiency

2018 ◽  
Vol 17 (14) ◽  
pp. e2942
Author(s):  
I. Rivero Belenchón ◽  
B.T. Anton Eguia ◽  
C.B. Congregado Ruíz ◽  
V. Cabello Chaves ◽  
I. Osman García ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Renal Insufficiency ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Targeted Therapies ◽  
Renal Cell

scholarly journals Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency

2010 ◽  
Vol 21 (8) ◽  
pp. 1618-1622 ◽  
Author(s):  
G. Khan ◽  
A. Golshayan ◽  
P. Elson ◽  
L. Wood ◽  
J. Garcia ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Renal Insufficiency ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell

Efficacy and toxicity of sunitinib in renal insufficiency patients with metastatic renal cell carcinoma.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15573-e15573
Author(s):  
Ki Hyang Kim ◽  
Sun Young Rha ◽  
Ho Young Kim ◽  
Hye Ryun Kim ◽  
Jong-Mu Sun ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Renal Impairment ◽  
Renal Insufficiency ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Performance Status ◽  
Cell Cancer ◽  
Progression Free Survival ◽  
Ecog Performance Status

e15573 Background: We investigated the efficacy and toxicity of sunitinib in renal insufficiency patients with metastatic renal cell carcinoma (mRCC). Methods: From Korean Renal Cell Cancer Registry (KRCCR, http://kcsg-rcc.or.kr), we searched renal insufficiency patients with mRCC treated with sunitinib as a first-line treatment between January 2008 and May 2012. The Crockcroft-Gault formula was used for calculation of glomerular filtration rate and selected patients with chronic renal failure not requiring dialysis. Patients characteristics, clinical outcomes, toxicities were evaluated. The patients were divided by 2 groups based on the National Kidney Foundation definition of renal impairment and overall survival (OS) and progression-free survival (PFS) were obtained. Results: From total 997 enrolled from KRCCR, 34 patients were evaluated. Patients characteristics included: median age 66 years, ECOG performance status of 0 and 1 were 90%, and median GFR 46.5 ml/min/1.73m2 (range, 21.1-59.5). The starting dose of sunitinib was 50 mg for 22 patients and 37.5 mg for 12 patients. A schedule of sunitinib was 4 weeks on-2 weeks off for 31 patients, 2 weeks on-2 weeks off for 1 patient and daily for 2 patients. Best response was partial response (N=8) or stable disease (N=12). The median OS and PFS was 26.3 (95% CI: 17.1-35.3) and 12.2 (95% CI: 10.2-13.2) months, respectively. Log rank analysis revealed that severity of renal impairment was significantly associated with PFS but not with OS. Most common adverse events (AEs) of non-hematologic toxicities were stomatitis, rash, general edema and fatigue. The most common grade ≥3 AEs were fatigue, neutropenia and thrombocytopenia. Conclusions: Renal insufficiency patients with metastatic RCC did not impact on the efficacy of sunitinib and did not increased toxicities. Clinicians should not hesitate to treat renal insufficiency patients with metastatic renal cell carcinoma.

1103: Laparoscopic Salvage Nephrectomy after Targeted Neoadjuvant Therapy for Metastatic Renal Cell Carcinoma: Initial Results

2007 ◽  
Vol 177 (4S) ◽  
pp. 364-364 ◽  
Author(s):  
Surena F. Matin ◽  
Christopher G. Wood ◽  
Shi-Ming Tu ◽  
Nizar M. Tannir ◽  
Eric Jonasch
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Neoadjuvant Therapy ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Initial Results

637: Establishing a Porcine Model for the Accelerated Development of Cancer Vaccines for Patients with Metastatic Renal Cell Carcinoma

2005 ◽  
Vol 173 (4S) ◽  
pp. 173-174
Author(s):  
Quinton V. Cancel ◽  
Benjamin K. Yang ◽  
Zhen Su ◽  
Jens Dannull ◽  
Philipp Dahm ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Cancer Vaccines ◽  
Porcine Model

1716: Pharmaco-Angio-CT is Superior to 4 Phase Helical CT in the Detection of Recurrent Metastatic Renal Cell Carcinoma

2006 ◽  
Vol 175 (4S) ◽  
pp. 551-552
Author(s):  
Erich K. Lang ◽  
Richard J. Macchia ◽  
Raju Thomas ◽  
Ronald Davis ◽  
Douglas Slakey ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Helical Ct ◽  
Angio Ct

396: HSP27 Expression in Primary and Metastatic Renal Cell Carcinoma

2006 ◽  
Vol 175 (4S) ◽  
pp. 129-129
Author(s):  
Richard E. Zigeuner ◽  
Nikolaus Droschl ◽  
Volkmar Tauber ◽  
Peter Rehak ◽  
Cord Langner
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Hsp27 Expression
Sign in / Sign up

Export Citation Format

Share Document